CA2163716A1 - Compositions pharmaceutiques a base de verotoxine et traitements medicaux qui l'utilisent - Google Patents

Compositions pharmaceutiques a base de verotoxine et traitements medicaux qui l'utilisent

Info

Publication number
CA2163716A1
CA2163716A1 CA002163716A CA2163716A CA2163716A1 CA 2163716 A1 CA2163716 A1 CA 2163716A1 CA 002163716 A CA002163716 A CA 002163716A CA 2163716 A CA2163716 A CA 2163716A CA 2163716 A1 CA2163716 A1 CA 2163716A1
Authority
CA
Canada
Prior art keywords
verotoxin
pharmaceutical compositions
medical treatments
cancer
verotoxins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002163716A
Other languages
English (en)
Other versions
CA2163716C (fr
Inventor
Clifford A. Lingwood
Hannah Farkas-Himsley
Robert Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002163716A priority Critical patent/CA2163716C/fr
Publication of CA2163716A1 publication Critical patent/CA2163716A1/fr
Application granted granted Critical
Publication of CA2163716C publication Critical patent/CA2163716C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002163716A 1995-11-24 1995-11-24 Compositions pharmaceutiques a base de verotoxine et traitements medicaux qui l'utilisent Expired - Fee Related CA2163716C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002163716A CA2163716C (fr) 1995-11-24 1995-11-24 Compositions pharmaceutiques a base de verotoxine et traitements medicaux qui l'utilisent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002163716A CA2163716C (fr) 1995-11-24 1995-11-24 Compositions pharmaceutiques a base de verotoxine et traitements medicaux qui l'utilisent

Publications (2)

Publication Number Publication Date
CA2163716A1 true CA2163716A1 (fr) 1997-05-25
CA2163716C CA2163716C (fr) 2009-05-19

Family

ID=4157034

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002163716A Expired - Fee Related CA2163716C (fr) 1995-11-24 1995-11-24 Compositions pharmaceutiques a base de verotoxine et traitements medicaux qui l'utilisent

Country Status (1)

Country Link
CA (1) CA2163716C (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051326A1 (fr) * 1997-05-16 1998-11-19 Hsc Research And Development Limited Partnership Inhibition de l'angiogenese au moyen de verotoxines
WO1999038530A1 (fr) * 1998-01-28 1999-08-05 University Of Bristol Agent capable de moduler l'activite liee a un glycosphingolipide, agissant ainsi sur un trouble immunitaire
WO2000029556A2 (fr) * 1998-11-17 2000-05-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification des glycosphingolipides qui favorisent la penetration du vih-1 dans les cellules
US7846435B1 (en) 1998-05-20 2010-12-07 Teijin Limited Humanized antibodies that recognize Verotoxin II and cell line producing same

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051326A1 (fr) * 1997-05-16 1998-11-19 Hsc Research And Development Limited Partnership Inhibition de l'angiogenese au moyen de verotoxines
WO1999038530A1 (fr) * 1998-01-28 1999-08-05 University Of Bristol Agent capable de moduler l'activite liee a un glycosphingolipide, agissant ainsi sur un trouble immunitaire
US7846435B1 (en) 1998-05-20 2010-12-07 Teijin Limited Humanized antibodies that recognize Verotoxin II and cell line producing same
WO2000029556A2 (fr) * 1998-11-17 2000-05-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification des glycosphingolipides qui favorisent la penetration du vih-1 dans les cellules
WO2000029556A3 (fr) * 1998-11-17 2000-11-23 Us Health Identification des glycosphingolipides qui favorisent la penetration du vih-1 dans les cellules

Also Published As

Publication number Publication date
CA2163716C (fr) 2009-05-19

Similar Documents

Publication Publication Date Title
BR9406893A (pt) Emprego de nona- e decapeptideos para a preparação de um medicamento para o combate da aids
AU8469498A (en) Peptide derivatives or pharmaceutically acceptable salts thereof, method for producing the same, use of said derivatives and pharmaceutical composition
MX9302038A (es) Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s.
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
CA2373794A1 (fr) Compositions et utilisation d'et743 pour le traitement du cancer
MY107088A (en) Plaster used as therapeutic system for the administration of active substances to the skin, which exhibits a graduated active substance release,process for the production of the plaster and use thereof
HUP9900905A2 (hu) D4-Vitamin származékok alkalmazása rák kezelésére szolgáló gyógyászati készítmények előállítására
BR9608731A (pt) Uso de derivados de 1,2,4-triazol para produção de um medicamento para tratamento de câncer
WO2000072823A8 (fr) Preparations pour l'application d'agents anti-inflammatoires
CA2163716A1 (fr) Compositions pharmaceutiques a base de verotoxine et traitements medicaux qui l'utilisent
CA2116179A1 (fr) Compositions pharmaceutiques avec verotoxine et utilisation dans des traitements medicamenteux
AU5691796A (en) Terpenoidic derivatives useful as antitumor agents
TR200401810T4 (tr) Kısırlık tedavisinde fsh'ın kullanılması
CA2283739A1 (fr) Acide ascorbique agissant comme adjuvant dans le traitement de tumeurs malignes par chimiotherapie et radiotherapie
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
HUP0004647A3 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
CA2097878A1 (fr) Agent therapeutique pour la neutropenie
IT8448710A1 (it) Riduzione degli effetti tossici causati da farmaci antrachinonici
James Cidofovir recommended for approval for CMV retinitis
KR950023398A (ko) 미용죽염(美容竹鹽)
MX9605916A (es) Compuestos bioaromaticos que llevan un grupo adamantilo en para, composiciones farmaceuticos y cosmeticas que los contienen y utilizaciones.
RU96110391A (ru) Способ лечения ожогов глаз и травматических эрозий роговицы
MD982F1 (ro) Produs profilactic curativ
UA31644A (uk) Препарат "інол"для лікування раку молочної залози
IL92665A0 (en) Medical cream against severe skin diseases including skin cancer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151124